Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
07 févr. 2023 16h05 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 févr. 2023 16h05 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h00 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics to Present at Upcoming Investor Conferences
22 nov. 2022 16h05 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h00 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
04 nov. 2022 10h00 HE
|
Chinook Therapeutics, Inc.
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is...
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
03 nov. 2022 10h00 HE
|
Chinook Therapeutics, Inc.
Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12...
Chinook Therapeutics to Present at Upcoming Investor Conferences
02 nov. 2022 16h00 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
14 oct. 2022 08h00 HE
|
Chinook Therapeutics, Inc.
Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the...
Chinook Therapeutics to Present at Upcoming Investor Conferences
01 sept. 2022 16h05 HE
|
Chinook Therapeutics, Inc.
SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines...